Medlab Clinical Limited (ASX:MDC)
Medlab Clinical Limited (ASX:MDC) is a biotechnology company building products that are scientifically optimised for a better life, specialising in oncology and enhanced drug delivery.
Medlab has a portfolio of novel cannabinoid-based assets enhanced by its leading drug delivery platform. The Company's lead drug candidate, NanaBis, is an opioid alternative for cancer-induced pain management.
Core to Medlab's value proposition is NanoCelle, the Company's patented sub-micron drug delivery platform that vastly improves drug solubility issues and enables faster absorption and metabolism of active ingredients. NanoCelle underpins the Company's growth strategy by providing near-term partnering opportunities while enhancing its pharma portfolio.